Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 183 results

Notice of Special Interest: Advancing Research for Tickborne Diseases (TBDs)

Notice of Special Interest
Tuesday, November 12, 2019
Sunday, January 8, 2023
NOT-AI-20-005

Funding Opportunity Purpose

Notice Special Interest: Advancing Research Tickborne Diseases TBDs) Notice Number: NOT-AI-20-005 Key Dates Release Date: November 12, 2019 First Available Due Date: January 05, 2020 Expiration Date: January 08, 2023 Related Announcements PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) Issued National Institute Allergy Infectious Diseases NIAID ) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Mental Health NIMH ) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH ) Purpose purpose this Notice to announce the National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), National Institute Mental Health NIMH), National Institute Neurological Disorders Stroke NINDS), the National Center Complementary Integrative Health NCCIH) encourage new applications advance research activities relevant the five strategic priorities identified the recently released NIH Strategic Plan Tickborne Disease Research: Improve fundamental knowledge TBDs to understand host, vector, pathogen factors drive TBD pathogenesis transmission. Elucidate host immune mechanisms response and exploited TBD pathogens. Advance research improve diagnosis TBDs using both host- pathogen-targeted approaches, including research rapid diagnostics multiplex platform approaches detect multiple tickborne pathogens. Accelerate research improve TBD prevention by supporting science design, develop, evaluate vaccines, vector control strategies, other prevention approaches. Promote research improve treatment all forms TBDs, including studies develop effective therapies treat symptoms persist after TBD treatment, therapies non-infectious TBDs, new antimicrobials. Support tools resources advance research understanding, preventing, diagnosing, treating TBDs, including repositories, genomic resources, animal models, preclinical services aid development assessment diagnostic, vaccine, therapeutic candidates. NIAID: NIAID support research the biology tickborne pathogens, vectors, animal reservoirs, human hosts, the interactions among elements they help understand underlying causes human disease. NIAID interested applications the basic science behind tickborne infections in applications seeking develop new approaches prevent, diagnose, treat those infections. NIAID also support research non-infectious TBDs, particularly alpha-gal syndrome. focus research this syndrome to understand pathogenesis develop improved diagnostics therapeutic approaches. NIAMS : NIAMS interested supporting research studies human immunity its role the initiation propagation Lyme arthritis. of systems biology approaches identify critical cellular molecular pathways involved pathogenesis encouraged. interests include studies the joint tissue remodeling pathways the cross-talk a wide range hematopoietic other cell types Lyme arthritis. Please note, NIAMS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NIMH: As lead federal agency research mental disorders, NIMH interested the following areas: Basic mechanistic neuroscience studies persistent effects Lyme disease brain signaling, circuits, proximal effects functional processes such cognition are impaired mental illnesses. Research illuminate mechanisms which tick-borne diseases lead specific psychiatric complications. Research understand neurobiological basis the impact tick-borne diseases specific domains functions relevant mental health, informed the Research Domain Criteria RDoC) approach. Research decrease burden acute chronic psychiatric complications Lyme disease other tick-borne diseases. Please note, NIMH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NINDS : NINDS interested supporting research the basic biology mechanisms the neurological consequences tick-borne diseases. includes developing animal cell models will facilitate studying nervous system pathogenesis these diseases developing new approaches diagnose treat neurological complications. Please note, NINDS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NCCIH: NCCIH support research the mechanisms which complementary integrative health approaches improve tick-borne disease TBD) treatment and/or post-TBD symptom care. Complementary integrative approaches include mind/brain-focused practices i.e., meditation, hypnosis), body-based approaches i.e., acupuncture, massage, spinal manipulation), meditative exercise i.e., yoga, tai chi, qi gong), natural products i.e., botanicals, dietary supplements, probiotics), isolation in combination conventional medical treatments. NCCIH not accept clinical trial measures efficacy effectiveness any intervention through NOSI. NCCIH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. Application Submission Information notice applies due dates or after January 5, 2020 subsequent receipt dates through January 8, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice. PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include ldquo;NOT-AI-20-005” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries to: Samuel Perdue, Ph.D. National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3341 E-mail: sperdue@nih.gov Yisong Wang, PhD. National Center Complementary Integrative Health NCCIH) Telephone: 301-480-9483 E-mail: yisong.wang@nih.gov Su-Yau Mao, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: maos2@mail.nih.gov Sarah H. Lisanby, M.D.. National Institute Mental Health NIMH) Telephone: 301-451-3029 Email: lisanbysh@mail.nih.gov Wong, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1431 Email: wongm@ninds.nih.gov

Support of Competitive Research (SCORE) Pilot Project Award (SC2 - Clinical Trial Not Allowed)

PAR
Thursday, October 24, 2019
Workforce Diversity
Thursday, September 8, 2022
PAR-20-040

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

Support of Competitive Research (SCORE) Research Advancement Award (SC1 - Clinical Trial Not Allowed)

PAR
Thursday, October 24, 2019
Workforce Diversity
Thursday, September 8, 2022
PAR-20-039

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

Support of Competitive Research (SCORE) Research Continuance Award (SC3 - Clinical Trial Not Allowed)

PAR
Thursday, October 24, 2019
Workforce Diversity
Thursday, September 8, 2022
PAR-20-041

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)

RFA
Friday, October 4, 2019
Friday, September 9, 2022
R41/R42
RFA-NS-20-009

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required)

RFA
Friday, October 4, 2019
Heal, Translational Research, Clinical Trials Research
Friday, September 9, 2022
R41/R42
RFA-NS-20-008

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Not Allowed)

RFA
Friday, October 4, 2019
Friday, September 9, 2022
R43/R44
RFA-NS-20-011

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 - Clinical Trial Required)

RFA
Friday, October 4, 2019
Heal, Translational Research, Clinical Trials Research
Friday, September 9, 2022
R43/R44
RFA-NS-20-010

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Basic Experimental Studies with Humans Required)

PAR
Wednesday, September 18, 2019
Thursday, March 18, 2021
R01
PAR-19-384

Funding Opportunity Purpose

This funding opportunity announcement (FOA) solicits research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. Types of projects submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical and/or behavioral outcomes in humans to understand fundamental aspects of phenomena related to social connectedness and isolatedness. NIH considers such studies as prospective basic science studies involving human participants that meet the NIH definition of basic research and fall within the NIH definition of a clinical trials (see, e.g., NOT-OD-19-024)

Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed)

PAR
Wednesday, September 18, 2019
Thursday, March 18, 2021
R01
PAR-19-373

Funding Opportunity Purpose

This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOAs companion for basic experimental studies with humans.

Pages